Sparrow Pharmaceuticals today today announced that the first patient has been enrolled in its new Phase 2b clinical trial evaluating clofutriben to improve glycemic control and metabolic health in patients who have difficult-to-control type 2 diabetes (T2D) with elevated cortisol (EC), a prevalent population with high unmet needs.

Sparrow Pharmaceuticals today announced the close of a $95 million Series B financing to support development of the company’s lead candidate clofutriben for the treatment of type 2 diabetes (T2D) with elevated cortisol (EC).

Sparrow Pharmaceuticals is collaborating with the University of Oxford and the University of Sheffield on DC-MACS, an investigator led, Phase 2 clinical study in the United Kingdom of clofutriben (SPI-62) for the treatment of autonomous cortisol secretion (ACS).

Sparrow Pharmaceuticals will present interim data from the ongoing Phase 2 trial of lead agent clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the American College of Rheumatology Convergence 2024 conference. Sparrow also announced that the trial has been expanded with a fifth cohort based on encouraging results from the first four cohorts.

Sparrow Pharmaceuticals announced that the Phase 2 RESCUE trial of clofutriben for the treatment of endogenous Cushing’s syndrome is complete. Clofutriben has also been granted Orphan Drug Designation by the FDA for the treatment of endogenous Cushing’s syndrome.

Sparrow Pharmaceuticals today announced that it presented new data of its HSD-1 inhibitor, clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the German Congress of Rheumatology (DGRh Kongress 2024) in Dusseldorf, Germany.

Sparrow Pharmaceuticals today presented data from an ongoing Phase 2 clinical trial that suggest HSD-1 inhibition can allow for effective treatment with glucocorticoid medicines with fewer side effects.

Sparrow Pharmaceuticals announced today that, to date, the HSD-1 inhibitor clofutriben (SPI-62) has normalized urine free cortisol (UFC) in >60% of patients with endogenous Cushing’s syndrome (EnCS) without suppressing serum cortisol to levels considered to indicate risk for adrenal insufficiency (AI).

Sparrow Pharmaceuticals’ David Katz, PhD, to Receive Outstanding Innovation Award at the 2024 Annual Endocrine Society Conference

Sparrow Pharmaceuticals has continued to expand its PROST! Phase 2 clinical trial (NCT05436652) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) with a fourth cohort.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of autonomous cortisol secretion (ACS).

Sparrow Pharmaceuticals today announced the expansion of its PROST! Phase 2 clinical trial of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.

Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.

Sparrow Pharmaceuticals will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference.

Sparrow Pharmaceuticals presented an ePoster on SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).

Sparrow Pharmaceuticals has expanded its Phase 2 clinical trial of prednisolone in combination with SPI-62 for the treatment of polymyalgia rheumatica (PMR) with the introduction of a second cohort to the study.

Sparrow Pharmaceuticals today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting. The presentation titled, “Toward Safer Glucocorticoid Therapy” examined the ability of SPI-62 to mitigate the adverse effects of exogenously administered corticosterone (CORT) in mouse, with results suggesting SPI-62 has the potential to prevent the adverse effects of glucocorticoids.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in a phase 2 clinical trial of prednisolone in combination with SPI-62, Sparrow’s potent and selective investigational HSD-1 inhibitor, for the treatment of polymyalgia rheumatica (PMR), a common autoimmune disease that causes widespread muscle pain and stiffness primarily in adults over 50. A fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.

Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).